Turn Therapeutics Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Bradley E. Burnam
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 250 N Westlake Blvd Westlake Village CA United States of America 91362
- IPO Date
- Oct 8, 2025
- CIK
- 0002023016
- Website
- turntherapeutics.com
- Similar Companies
- Business
- Turn Therapeutics Inc. functions as a clinical-stage biotechnology enterprise focused on developing advanced pharmaceutical and medical device solutions for various dermatological conditions, wound healing, and infectious diseases. The company utilizes its patented PermaFusion® drug delivery system, engineered to enable active ingredients to deeply permeate skin, nails, and mucous membranes, thus enhancing drug stability and effectiveness with potentially lower concentrations. This innovative platform supports a pipeline addressing significant unmet needs, particularly in areas like moderate to severe eczema and onychomycosis, building upon its foundation of existing FDA-cleared medical devices for a range of skin and wound management applications. Expanding its scope, the company is also exploring global health initiatives, including the development of thermostable vaccine delivery technologies. Turn Therapeutics initiated trading on Nasdaq under the symbol TTRX in October 2025, further bolstered by strategic alliances, notably a global supply, development, and license agreement with Medline. Founded in 2015, the firm maintains its base in Westlake Village, California.
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
Why Is Turn Therapeutics Stock Trading Higher Today?
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Turn Therapeutics (NASDAQ:TTRX) Trading 6% Higher – Should You Buy?
Head-To-Head Review: Athersys (NASDAQ:ATHX) versus Turn Therapeutics (NASDAQ:TTRX)
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX)
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More